Concepedia

The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis

John Foley, Cynthia Carrillo-Infante, Jonathan Smith, Karleyton C. Evans, Pei‐Ran Ho, Lily Lee, Rachna Kasliwal, Martin Stangel, Patrick Vermersch, Michael Hutchinson,

Multiple Sclerosis and Related Disorders · 2019 · 33 citations · 19 references

DOI

Concepts

References

19

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Jacques Ferlay, Hai‐Rim Shin, Freddie Bray et al. · International Journal of Cancer · 2010 · 21.4K citations

, , +16

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Chris H. Polman, Paul O’Connor, Eva Havrdová et al. · New England Journal of Medicine · 2006 · 3.3K citations · Full text

, , +14

A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

David H. Miller, Omar Khan, William Sheremata et al. · New England Journal of Medicine · 2003 · 1.2K citations · Full text

, , +16

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

Gary Bloomgren, Sandra Richman, Christophe Hotermans et al. · New England Journal of Medicine · 2012 · 1.2K citations · Full text

, , +17

THE INTERNATIONAL CONFERENCE ON HARMONIZATION GOOD CLINICAL PRACTICE GUIDELINE

Quality Assurance · 1999 · 508 citations

, , +13